ERBB2 and breast cancer: Both in the case of trastuzumab and tucatinib, we observed that the sensitivity of our model was reduced if compared to the response of the human HER2+++ breast cancer cell line BT-474 (halved for trastuzumab and three times lower for tucatinib).